PHENAZONE

Phenazone is derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2. 
Phenazone has a role as a non-narcotic analgesic, an antipyretic, a non-steroidal anti-inflammatory drug, a cyclooxygenase 3 inhibitor, a xenobiotic and an environmental contaminant.
Phenazone is an antipyretic agent used for the symptomatic treatment of acute otitis media, most commonly in combination with benzocaine. 

CAS Number: 60-80-0
Molecular Formula: C11H12N2O
Molecular Weight: 188.23
EINECS Number: 200-486-6

Synonyms: Antipyrine, Diméthyloxyquinazine, Oxydiméthylquinazine, Oxydiméthylquinizine, Pyrazoline, 1,2-dihydro-1,5-dimethyl-2-phenyl-3h-pyrazol-3-on;1,5-Dimethyl1-2-phenyl-3-pyrazolone;phenazone(pharmaceutical);Phenozone;Phenyldimethyl isopropyl pyrazolone;Phenylon;Phenylone;Pyrazophyl

Phenazone widely used analgesics and antipyretics, antipyrine was gradually replaced in common use by other medications including phenacetin (itself later withdrawn because of safety concerns), aspirin, paracetamol and modern NSAIDs such as ibuprofen.
Phenazone, also known as antipyrine, antipyrin, phenazon, phenazone, analgesine, and fenazone, is a synthetic organic compound belonging to the pyrazolone class of chemicals.
Phenazone is historically important as an analgesic and antipyretic drug and is also used as a reference compound in pharmaceutical and drug-metabolism research. 

Phenazone is C₁₁H₁₂N₂O, and its molecular weight is approximately 188.23 g/mol.
Phenazones CAS Registry Number is 60-80-0, while PubChem identifies Phenazone as CID 2206. 
Phenazone is structurally classified as a pyrazolone derivative, containing a five-membered nitrogen-containing heterocyclic ring with a carbonyl group.

Phenazones structure includes methyl substituents and a phenyl group attached to the pyrazolone framework, giving the molecule its characteristic chemical and pharmacological properties. 
The systematic chemical name commonly associated with Phenazone is 1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one.
Other systematic descriptions include 1-phenyl-2,3-dimethyl-5-pyrazolone and 2,3-dimethyl-1-phenyl-5-pyrazolone. 

Phenazone is also known by a particularly large number of historical and pharmaceutical synonyms.
These include Antipyrine, Antipyrin, Analgesine, Phenazonum, Phenazon, Fenazone, Phenylon, Phenylone, Sedatin, Sedatine, Azophen, Azophene, Oxydimethylquinazine, and NSC 7945. 

Phenazone belongs to a broader group of synthetic pyrazolone compounds that became important in the development of early pharmaceutical analgesics.
Phenazone s historical significance comes partly from the fact that it was among the early synthetic medicines developed for reducing pain and fever. 
As a pharmaceutical compound, Phenazone has traditionally been characterized as an analgesic, antipyretic, and anti-inflammatory agent.

Phenazone has been administered orally and has also been used in preparations intended for application to the ear. 
Phenazone is not a simple aromatic amine or conventional carboxylic acid because its nitrogen atoms are incorporated into a heterocyclic pyrazolone structure.
The presence of the carbonyl group and the two nitrogen atoms strongly influences its electronic properties, polarity, and interactions with biological systems. 

The molecule contains one oxygen atom, two nitrogen atoms, and eleven carbon atoms.
Phenazone s molecular structure therefore combines an aromatic phenyl group with a nitrogen-containing heterocycle, producing a relatively compact heteroaromatic pharmaceutical molecule. 
Phenazone has also been important in pharmacological research because it is metabolized by the liver and can be used to investigate drug-metabolizing enzyme activity.

Changes in the metabolism of Phenazone have historically been used as an experimental indicator of alterations in hepatic microsomal enzyme activity. 
This metabolic characteristic makes Phenazone useful beyond its direct therapeutic applications.
Researchers have used it as a probe compound when studying how diseases, medications, environmental factors, or other conditions influence drug metabolism. 

Phenazone has a long history in medicinal chemistry and pharmaceutical development.
Phenazone s introduction represented an important stage in the transition from naturally derived remedies toward systematically designed synthetic analgesic and antipyretic compounds. 
Phenazone is closely related chemically to other pyrazolone-based pharmaceuticals, including several historically important analgesic compounds.

These structural relationships make Phenazone relevant when studying the chemistry, pharmacology, and historical development of pyrazolone derivatives. 
Phenazone is also represented in major chemical and pharmaceutical databases under both its chemical and pharmaceutical names.
NIST records its molecular formula, molecular weight, CAS number, structure, InChI information, and numerous historical synonyms, while PubChem provides extensive chemical and biological information. 

From a chemical perspective, Phenazone is a neutral organic molecular compound rather than an inorganic salt or metal-containing substance.
Phenazone s molecular architecture gives it properties suitable for pharmaceutical formulation and analytical investigation. 
Phenazone has also been investigated in relation to its biological transformation and elimination from the body.

Phenazone s metabolism produces several derivatives, making Phenazone useful for studying enzymatic oxidation and related biochemical pathways. 
Phenazone became recognized primarily for its ability to reduce pain and fever.
Although many newer analgesic and antipyretic drugs have subsequently been developed, Phenazone remains chemically and historically significant as an early synthetic pharmaceutical. 

Phenazone's pharmaceutical identity is reflected in the international nonproprietary name Phenazone.
The name Antipyrine is also extensively used in chemical, medical, and historical literature to refer to the same substance. 
Phenazone is a synthetic pyrazolone compound with the molecular formula C₁₁H₁₂N₂O and CAS No. 60-80-0.

Phenazone s importance extends from early analgesic and antipyretic medicine to pharmaceutical research, drug-metabolism studies, analytical chemistry, and the broader history of synthetic medicinal chemistry. 
Phenazone has also been investigated as a probe drug for evaluating hepatic metabolic capacity because its disposition is influenced by the activity of drug-metabolizing enzymes in the liver.
Changes in its clearance and metabolite formation can provide information about alterations in hepatic function and oxidative metabolism. 

The pharmacokinetics of Phenazone have been extensively characterized in humans following both oral and intravenous administration.
Studies have shown that Phenazone is efficiently absorbed and undergoes extensive hepatic metabolism before its metabolites are eliminated from the body. 
Phenazone produces several identifiable oxidative metabolites that are useful in pharmaceutical research.

Among the principal metabolites are 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine. 
The formation of 4-hydroxyantipyrine has been particularly important in pharmacokinetic investigations.
Measurement of this metabolite can help researchers characterize the oxidative metabolism of Phenazone under different physiological and experimental conditions. 

Phenazone metabolism can be influenced by external factors such as smoking and co-administered medicines.
Clinical research has demonstrated differences in Phenazone half-life and metabolite formation between smokers and nonsmokers, illustrating its sensitivity to changes in hepatic enzyme activity. 
Phenazone has therefore been used in studies investigating enzyme induction and changes in hepatic drug metabolism.

Phenazone s metabolic behavior can provide an indirect indication of how exposure to certain substances affects the body's capacity to transform pharmaceutical compounds. 
Phenazone has also been investigated in patients with different forms of liver disease.
Research has examined its pharmacokinetic behavior in conditions including cirrhosis, fatty liver, hepatitis, and cholestasis. 

Because Phenazone has relatively low protein binding and low extraction characteristics, changes in its clearance can provide useful information about hepatic function.
This property has contributed to its historical use in pharmacokinetic approaches for assessing impaired liver metabolism. 
Phenazone has also been used in research examining interactions between medicines.

Changes in its half-life, clearance, or metabolite formation can help researchers determine whether another compound influences hepatic metabolic pathways. 
Phenazone is particularly useful because its metabolic products can be measured in biological samples.
Urinary excretion of Phenazone metabolites has been investigated as an indicator of differences in metabolic activity between individuals and experimental groups. 

From a chemical perspective, Phenazone is a relatively compact heterocyclic molecule containing a pyrazolone ring and a phenyl substituent.
NIST identifies its molecular formula as C₁₁H₁₂N₂O, its molecular weight as 188.2258 g/mol, and its CAS Registry Number as 60-80-0. 
The extensive synonym history of Phenazone reflects its long pharmaceutical and chemical history.

Names recorded by NIST include Antipyrine, Antipyrin, Analgesine, Fenazone, Phenazon, Phenazone, Phenazonum, Phenylon, Sedatin, and several systematic pyrazolone names. 
Phenazone has also been classified within the broader pyrazolone family of heterocyclic compounds.
This classification places it alongside other historically important pharmaceutical compounds developed around substituted pyrazolone structures. 

Melting point: 109-111 °C (lit.)
Boiling point: 319 °C
Density: 1.19 g/cm3
Refractive index: 1.5850 (estimate)
Storage temp.: 2-8 °C
Solubility: H2O: soluble 1 g in less than 1 mL
Form: Crystalline Powder
pKa: pKa 1.4 (Uncertain)
Color: White
Biological source: Rabbit
Water solubility: 1000 g/L (20 °C)
Merck: 14,716
BRN: 157775
Stability: Stable. Incompatible with ammonia, strong acids, alkalies, strong oxidizing agents, metallic salts, phenol.
InChI: 1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3
InChIKey: VEQOALNAAJBPNY-UHFFFAOYSA-N
SMILES: CN1N(C(=O)C=C1C)c2ccccc2
LogP: 0.380

Phenazone is a pyrazolone derivative chemically related to aminophenazone. 
Some regulatory authorities have imposed restrictions on its use on these grounds. 
However, a recent international study showed no statisticallybased evidence of an association with agranulocytosis or aplastic anaemia. 

Phenazone share with aminophenazone the propensity to produce potentially carcinogenic nitrosamines.
Colorless crystal or white crystalline powder. 
Soluble in benzene, ethanol, water, chloroform, slightly soluble in ether. Odorless, slightly bitter.

Phenazone has several additional characteristics that are important when considering its chemical and pharmaceutical significance.
Phenazone s relatively simple molecular structure, well-defined metabolism, and long history of medicinal use have made it a useful compound for both pharmaceutical science and experimental pharmacology. 

The pyrazolone ring is the central structural feature responsible for classifying Phenazone as a pyrazolone derivative.
This heterocyclic framework contains two nitrogen atoms and one carbonyl group and is substituted with methyl and phenyl groups. 
Phenazone has a molecular weight of 188.23 g/mol and the molecular formula C₁₁H₁₂N₂O.

Phenazone s relatively low molecular mass and neutral molecular structure are consistent with its historical development as an orally administered pharmaceutical compound. 
Phenazone has the CAS Registry Number 60-80-0, which is commonly used for its identification in chemical and pharmaceutical databases.
Phenazone is also registered under the name Antipyrine in several pharmacopoeial and chemical records. 

Phenazone is classified pharmacologically as a non-narcotic analgesic and antipyretic.
Phenazone has also been described within the non-steroidal anti-inflammatory drug group and belongs to the pyrazolone category of analgesic compounds. 
One of the most interesting aspects of Phenazone is its use as a model compound in drug-metabolism studies.

Its metabolism involves several hepatic cytochrome P450 enzymes, allowing researchers to investigate changes in oxidative drug-metabolizing activity. 
Phenazone is converted into several identifiable metabolites after administration.
Important metabolites include 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine, which arise through different oxidative metabolic pathways. 

The formation of these metabolites is particularly useful in pharmacokinetic research.
Measurements of Phenazone metabolites have historically been used to evaluate the activity of hepatic drug-metabolizing enzymes in humans. 
Several cytochrome P450 enzymes contribute to the metabolism of Phenazone.

Research has identified involvement of CYP1A2, CYP2B6, members of the CYP2C family, and CYP3A4 in the formation of its principal oxidative metabolites. 
Because multiple enzymes participate in its metabolism, Phenazone provides information about overall oxidative metabolic capacity rather than serving as a highly selective probe for only one enzyme.
This characteristic has nevertheless made it valuable in studies examining how diseases, drugs, and other factors alter hepatic metabolism. 

Phenazone has also been studied using both in-vivo and in-vitro approaches.
Comparisons between metabolite formation in humans and liver-derived experimental systems have demonstrated relationships between metabolic rates measured under different experimental conditions. 

Phenazone s metabolites can therefore provide information about the functional activity of hepatic metabolic pathways.
This has contributed to the use of Phenazone in pharmacokinetic investigations and studies of hepatic enzyme activity. 
Phenazone has historically been administered by mouth for its analgesic and antipyretic effects.

Phenazone has also been incorporated into preparations intended for use as ear drops, giving Phenazone applications beyond systemic oral therapy. 
Phenazone has been incorporated into combination pharmaceutical products as well.
For example, Phenazone has been combined with salicylic acid to form Phenazone salicylate, a distinct pharmaceutical compound documented in chemical databases. 

Phenazone is also chemically related to other pyrazolone analgesics.
Compounds such as propyphenazone share the antipyrine framework but contain additional structural substituents that modify their chemical and pharmacological properties. 
The historical importance of Phenazone extends beyond its direct pharmaceutical applications.

Phenazone represents an early example of synthetic medicinal chemistry in which a defined heterocyclic structure was developed into a clinically useful analgesic and antipyretic compound. 
Phenazone is therefore relevant to both pharmaceutical chemistry and chemical research.
Its combination of a well-characterized pyrazolone structure, established biological activity, and extensive metabolic data makes it a useful reference compound for studying synthetic drugs and their transformation in biological systems. 

In chemical databases, Phenazone is consistently associated with the synonyms Antipyrine, Antipyrin, Phenazon, Fenazone, and Analgesine.
These alternative names are important because older pharmaceutical literature frequently uses Antipyrine or Antipyrin rather than the modern international name Phenazone. 
Phenazone is a historically significant synthetic pyrazolone compound with established analgesic and antipyretic properties.

Phenazone s continuing importance in pharmaceutical research is strongly connected to its well-characterized hepatic metabolism and its use as a model compound for investigating drug-metabolizing enzyme activity. 
Phenazone therefore has significance beyond its historical role as an analgesic and antipyretic medicine.
It has become an established research compound for investigations involving pharmacokinetics, hepatic metabolism, drug interactions, enzyme activity, and liver function. 

From an industrial and pharmaceutical chemistry perspective, Phenazone is best recognized as a pyrazolone pharmaceutical and metabolic probe compound rather than as a general-purpose industrial chemical.
Phenazone s well-characterized structure, established metabolites, and extensive pharmacological literature continue to make it relevant to medicinal chemistry and pharmaceutical research. 

Its pharmaceutical history makes Phenazone particularly relevant to the development of synthetic analgesic and antipyretic chemistry.
Phenazone illustrates how heterocyclic chemistry contributed to the development of early synthetic medicines with defined chemical structures and reproducible pharmacological activity. 
Phenazone is also useful as a reference substance in analytical and pharmacological studies because its chemical identity and metabolic pathways are well documented.

Researchers can compare Phenazone concentrations and metabolite profiles to investigate pharmacokinetic differences between experimental conditions. 
Phenazone's established metabolism has additionally made it valuable for studying interindividual differences in drug disposition.
Factors affecting liver enzyme activity can alter the rate at which Phenazone is converted into its oxidative metabolites and subsequently eliminated. 

Uses:
Antipyrine has been used for immunoblotting. 
Phenazone has also been used as an internal reference marker for studying the transport characteristics of platinum-containing drug, cisplatin in the human placenta in vitro. 
Phenazone is an analgesic and antipyretic that has been given by mouth and as ear drops. 

Phenazone is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. 
Phenazone is primarily used as an analgesic and antipyretic pharmaceutical compound.
Its established pharmacological classification places it among pyrazolone analgesics and non-steroidal anti-inflammatory agents. 

One of the traditional applications of Phenazone is the relief of mild to moderate pain.
Phenazone s analgesic activity has made it historically important in the development and use of synthetic pain-relieving medicines. 
Phenazone has also been used as an antipyretic, meaning that it can be used to reduce elevated body temperature associated with fever.

This property contributed significantly to its historical pharmaceutical importance as an early synthetic medicine. 
Phenazone has been administered orally in pharmaceutical preparations.
Oral administration has historically been used when systemic analgesic and antipyretic effects were required. 

Another established application is its use in otic preparations and ear drops.
Phenazone can be incorporated into ear-drop formulations to provide local analgesic action for ear pain. 
Phenazone has been combined with local anesthetics in certain ear-drop formulations.

For example, benzocaine–phenazone preparations have been investigated and marketed for the management of ear pain associated with conditions such as acute otitis media. 
The combination of Phenazone with a local anesthetic provides a complementary approach to topical ear-pain management.
In these formulations, Phenazone provides analgesic activity while the accompanying anesthetic produces local anesthetic effects. 

Phenazone has also been used in combination pharmaceutical products with other active ingredients.
One documented example is Phenazone salicylate, a compound containing Phenazone and salicylic acid that has been recorded in chemical and pharmaceutical databases. 
Phenazone has applications in pharmaceutical research because its pharmacokinetic behavior is well characterized.

Phenazone have investigated its absorption, distribution, metabolism, and elimination following different routes of administration and pharmaceutical dosage forms. 
A particularly important non-therapeutic application of Phenazone is its use as a drug-metabolism probe.
Its metabolism by hepatic enzymes allows researchers to investigate changes in the activity of drug-metabolizing systems in the liver. 

Phenazone has been used to study how other medicines influence hepatic drug metabolism.
Changes in the clearance or metabolite profile of Phenazone can provide information about enzyme induction or inhibition caused by other substances. 
Phenazone is also useful for investigating the effects of diseases on hepatic metabolic capacity.

Phenazone metabolism has been studied in relation to alterations in liver function and different pathological conditions. 
Phenazone metabolism produces several identifiable metabolites that are useful in pharmacological research.
Important metabolites include 4-hydroxyantipyrine, norantipyrine, and 3-hydroxymethylantipyrine, which can be measured to investigate metabolic pathways. 

Because its metabolic products can be analyzed, Phenazone has been used in pharmacokinetic and clinical research.
Measurements of the parent compound and its metabolites can help researchers compare drug metabolism between individuals or experimental conditions. 
Phenazone is also used as a reference compound in studies of hepatic cytochrome P450 activity.

Phenazone s metabolism involves several oxidative enzyme systems, making it useful for examining broader changes in hepatic drug-metabolizing capacity. 
Phenazone has therefore been applied in research investigating drug–drug interactions.
Changes in Phenazone metabolism can help researchers determine whether another substance affects the activity of enzymes responsible for pharmaceutical metabolism. 

Phenazone has also been investigated in experimental pharmacology to better understand the biological mechanisms underlying analgesia.
Phenazone has examined relationships between Phenazone treatment, pain thresholds, and neurotransmitter systems involved in nociception. 
Its use as a metabolic probe is particularly valuable because Phenazone has a well-established chemical identity and relatively extensive pharmacokinetic literature.

This makes it a convenient reference substance for comparing metabolic activity under different experimental and clinical conditions. 
Phenazone has also been used in pharmaceutical investigations involving different dosage forms and administration routes.
Historical pharmacokinetic studies have examined oral, rectal, and topical administration and evaluated how formulation influences the resulting concentration profile. 

In analytical research, Phenazone and its metabolites can serve as measurable markers for investigating drug disposition.
Their detection and quantification can provide information about metabolic rate, enzyme activity, and elimination pathways. 
Phenazone is also relevant to the broader field of medicinal chemistry because it represents an important early pyrazolone pharmaceutical.

Phenazone s structure and pharmacological activity have provided a basis for studying other substituted pyrazolone compounds used in pharmaceutical development. 
Phenazone has consequently remained useful as a reference molecule even though many newer analgesic and antipyretic medicines have been developed.
Its historical pharmaceutical applications and well-characterized metabolism continue to make it relevant to pharmacological and biochemical research. 

Phenazone include analgesic and antipyretic therapy, topical ear-pain preparations, pharmaceutical combination products, pharmacokinetic research, and investigation of hepatic drug-metabolizing enzymes.
Its combination of established biological activity and extensively studied metabolism gives Phenazone continuing significance in pharmaceutical chemistry and biomedical research. 

Phenazone has been used extensively as a pharmacokinetic probe for studying oxidative drug metabolism in humans.
Because its clearance depends substantially on hepatic metabolic activity, researchers can use changes in Phenazone disposition to investigate how efficiently the liver processes certain drugs. 
One important research application is the assessment of hepatic microsomal enzyme activity.

Phenazone metabolism involves several cytochrome P450 enzymes, allowing its disappearance and metabolite formation to be used as indicators of broader oxidative metabolic capacity. 
Phenazone has historically been used in investigations of liver function and hepatic impairment.
Studies have examined its pharmacokinetics in conditions such as cirrhosis, fatty liver, hepatitis, and cholestasis because hepatic dysfunction can alter its clearance. 

Phenazone has also been investigated as a potential quantitative indicator of liver metabolic capacity.
Phenazone has compared Phenazone clearance and urinary metabolite excretion with established measures of hepatic function to determine how effectively the liver performs drug biotransformation. 
Another application is the investigation of drug-induced changes in hepatic metabolism.

Phenazone pharmacokinetics can change when other medicines influence hepatic enzymes, making it useful for experimental studies of metabolic induction and inhibition. 
Phenazone has consequently been used in studies of drug–drug interactions.
Phenazone can compare Phenazone clearance or metabolite formation before and after exposure to another pharmaceutical to investigate whether hepatic oxidative metabolism has been altered. 

Phenazone has also been applied to studies investigating the influence of disease states on drug metabolism.
Phenazone has examined changes in Phenazone elimination in patients with different disorders to distinguish alterations in hepatic metabolic activity from other pharmacokinetic factors. 
Phenazone is particularly useful for this purpose because several of its metabolites are well characterized.

Important products of its oxidative metabolism include 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine, which can be measured in pharmacokinetic studies. 
Measurement of 4-hydroxyphenazone or 4-hydroxyantipyrine has been investigated as a way of evaluating hepatic metabolic function.
Historical clinical research found relationships between urinary metabolite formation, Phenazone clearance, and quantitative measures of liver function. 

Phenazone has also been used to investigate how therapeutic treatments influence drug-metabolizing enzymes.
For example, researchers have evaluated changes in Phenazone elimination during treatment with other medicines to determine whether hepatic biotransformation was altered. 
Another research application involves examining interindividual differences in drug metabolism.

Differences in Phenazone clearance between individuals can provide information about variation in hepatic enzyme activity and the factors responsible for differences in pharmaceutical disposition. 
Phenazone has also been investigated in patients receiving complex medical treatments.

Phenazone s pharmacokinetic behavior has been used to study whether conditions such as nutritional support, chronic disease, or concomitant medication alter hepatic oxidative drug metabolism. 
Phenazone has applications in experimental pharmacology and biochemical research because its metabolic pathways can be reproduced in human liver microsomal systems.
These experimental systems have been used to identify which cytochrome P450 enzymes contribute to the formation of individual Phenazone metabolites. 

Phenazone is therefore useful for comparing the activity of different cytochrome P450 pathways.
Phenazone has linked different metabolic products with contributions from enzymes including CYP3A4 and CYP2C-family enzymes. 
Another use is the development and evaluation of pharmacokinetic models.

Phenazone concentration data can be analyzed to estimate parameters such as clearance and elimination rates in healthy individuals and patients with impaired hepatic function. 
Phenazone has also been employed in research involving limited-sampling pharmacokinetic approaches.
Clinical studies have investigated whether a limited number of concentration measurements can be used to estimate individual Phenazone pharmacokinetic parameters in patients with chronic liver disease. 

Its established pharmacokinetic profile also makes Phenazone valuable as a reference compound in pharmaceutical research.
Phenazone can use its known metabolic behavior when evaluating how experimental conditions or other compounds affect oxidative drug metabolism. 

Phenazone has additionally been used in investigations involving endocrine and metabolic disorders.
Studies have examined changes in Phenazone pharmacokinetics in conditions such as hyperthyroidism to investigate relationships between physiological status and hepatic microsomal enzyme activity. 

Safety Profile:
A human Doison bv 1 i an unspecified route. 
Moderately toxic via ingestion, subcutaneous, and intravenous routes. 
Questionable carcinogen with experimental tumorigenic data. 

Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Phenazone, also known as Antipyrine, is generally handled as a hazardous laboratory chemical, although the exact classification can vary between suppliers and jurisdictions.
Current safety data commonly identify oral acute toxicity as a concern, while some suppliers additionally classify the substance as irritating to the skin and eyes and capable of causing specific target-organ effects after exposure. 

One of the principal hazards associated with Phenazone is harmful effects if swallowed.
Several current safety data sheets classify Phenazone as Acute Toxicity Category 4 by the oral route with the hazard statement H302. 
Accidental ingestion should therefore be avoided during laboratory or industrial handling.

Appropriate hygiene practices include not eating, drinking, or smoking while working with the material and washing hands thoroughly after handling. 
Phenazone can also present a skin irritation hazard depending on the specific product classification.
Some current supplier data classify it as Skin Irritation Category 2 and recommend protective gloves and suitable protective clothing during handling. 

Direct contact with the eyes may cause irritation.
Safety information for Phenazone recommends suitable eye protection, while international chemical-safety guidance reports redness as a possible effect following eye exposure. 
Inhalation of Phenazone dust should also be avoided.

International chemical-safety guidance identifies coughing as a possible consequence of inhaling dust and recommends adequate ventilation or local exhaust during handling. 
Dust formation is particularly relevant when Phenazone is handled as a dry solid.
Laboratory safety information recommends avoiding the generation and dispersion of dust and using appropriate respiratory protection where engineering controls cannot adequately prevent airborne exposure. 

Phenazone is classified as a combustible solid in some current laboratory safety databases.
Although it does not have the extreme energetic properties associated with compounds such as nitroglycerin, it should nevertheless be kept away from uncontrolled ignition sources and excessive heat. 

Supply Of Phenazone: 
For further information about Phenazone, including available product grades, technical specifications, application suitability and supply options, please contact Ataman Kimya.